Compare ATMU & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | ACAD |
|---|---|---|
| Founded | 1958 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.4B |
| IPO Year | 2023 | 2000 |
| Metric | ATMU | ACAD |
|---|---|---|
| Price | $45.71 | $21.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $62.60 | $30.53 |
| AVG Volume (30 Days) | 641.8K | ★ 1.6M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | 12.61 | ★ 69.12 |
| EPS | ★ 1.37 | 0.51 |
| Revenue | ★ $1,764,300,000.00 | $726,437,000.00 |
| Revenue This Year | $14.05 | $18.71 |
| Revenue Next Year | $5.07 | $12.44 |
| P/E Ratio | ★ $34.91 | $107.35 |
| Revenue Growth | 5.67 | ★ 40.45 |
| 52 Week Low | $40.75 | $18.39 |
| 52 Week High | $66.50 | $30.96 |
| Indicator | ATMU | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 54.46 |
| Support Level | $43.69 | $21.44 |
| Resistance Level | $50.47 | $22.92 |
| Average True Range (ATR) | 1.43 | 0.57 |
| MACD | 0.48 | 0.39 |
| Stochastic Oscillator | 77.65 | 97.38 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.